FDA Assesses Its Role In Limiting Physician Access To Auxilium's Xiaflex

Deciding whether to mandate a Risk Evaluation and Mitigation Strategy when the safety of a product may be a function of the health care provider's skill is the question FDA is debating as it reviews Auxilium's Xiaflex for advanced Dupuytren's disease